Annals of Oncology· @Annals_Oncology · X·· 2 天前评分70
正文 · 原文
📢 #ESMO26 concomitant paper - Perioperative pembrolizumab or pbo + neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study.
🔗https://shorturl.at/6wrs1
@DrChrisHoimes
898 浏览 · 9 赞 · 3 转发 · 0 回复
会议摘要
4735O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.org来源：Annals of Oncology · x.com